Endoscopic versus Shunt Treatment of Hydrocephalus in Infants
婴儿脑积水的内镜与分流治疗
基本信息
- 批准号:10242095
- 负责人:
- 金额:$ 149.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-15 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:1 year oldAbdomenAccountingAffectAgeAge-YearsAmericanAnisotropyBrainCauterizeCerebral VentriclesCerebrospinal FluidCerebrospinal fluid shunts procedureCerebrumChildChildhoodClinical ResearchCognitiveCorpus CallosumCorticospinal TractsDataDevelopmentDiffusionDiffusion Magnetic Resonance ImagingFamilyHospital ChargesHydrocephalusImageInfantLanguageLength of StayLifeMeasuresMethodsMotorNCAM1 geneNeurologicNorth AmericaOperative Surgical ProceduresOutcomePediatric HospitalsPerformancePostoperative PeriodProceduresQuality of lifeRepeat SurgeryRiskShunt DeviceStructure of choroid plexusSurveysTimeToddlerTreatment FailureVentricularVentriculostomycohortinsightneurosurgeryoptimal treatmentsprimary outcomerandomized trialtertiary caretreatment armwhite matter
项目摘要
Hydrocephalus primarily affects infants under one year of age. The traditional treatment for hydrocephalus is
cerebrospinal fluid (CSF) shunt. Life-time complications of CSF shunts are high and expensive, with annual
hospital charges of nearly $2.0 billion, accounting for 3.1% of all pediatric hospital charges. As shunt
complications also adversely impact quality of life, it is not surprising that surveys of families affected by
hydrocephalus show that they desperately desire shunt-free treatment options. The most promising shunt-free
treatment for infant hydrocephalus is endoscopic third ventriculostomy with choroid plexus cauterization
(ETV+CPC), which our Hydrocephalus Clinical Research Network (HCRN) and others have shown to be safe
and viable. However, the cognitive outcome of ETV+CPC compared to shunt is not known. Our data suggest
that most families would accept the risks of ETV+CPC for the chance to be free of shunt, but only if initial
treatment with ETV+CPC will not lead to noticeable sacrifice in cognitive outcome compared to shunting. With
this U01 proposal, we aim: 1. To determine, in infants ≤12 months corrected age, with hydrocephalus requiring
treatment at tertiary care pediatric neurosurgery centers in North America, does ETV+CPC compared to shunt
result in non-inferior cognitive outcome at 12 months from surgery, as measured by Bayley Scales of Infant and
Toddler Development (Bayley-III) Cognitive Scale with a non-inferiority margin of 1.5. 2a. To determine, in
the same cohort, if ETV+CPC compared to shunt results in non-inferior Bayley-III Motor/Language Scales or
Vineland-3 Scales. 2b. To compare other measures of treatment performance (brain/ventricle volume,
treatment failure, hospital days, repeat surgery, use of imaging) and complications between treatment arms.
3a. To determine the effect of ETV+CPC and shunt on cerebral structural connectivity, with diffusion MR
fractional anisotropy (FA) in the corpus callosum 12 months after surgery. 3b. To define the relationships
between pre-operative brain/ventricular volume and cerebrospinal fluid (CSF) NCAM-1 level to post-operative
corpus callosum FA and Bayley-III Cognitive Scale 12 months after surgery. 3c. To define the relationships
between change in brain/ventricular volume (pre-operatively to 12 months post-operatively) to FA in the
corpus callosum and corticospinal tract and Bayley-III Cognitive and Motor Scales 12 months post-operatively.
To do this, we plan an RCT comparing ETV+CPC and shunt in infants with hydrocephalus, within the HCRN, a
committed group of 14 leading North American pediatric neurosurgical centers with a long track-record of
successful collaborative clinical research and RCTs in hydrocephalus. Optimal cognitive outcome, the primary
concern of families, will therefore, be our primary outcome. Assessment of dMRI, a validated, non-invasive
method of measuring white matter microstructural integrity and structural connectivity in the developing
brain, will provide further insight into the developmental consequences of these 2 treatments. This RCT will
help families determine the optimal treatment of hydrocephalus for their child.
脑积水主要影响一岁以下的婴儿。传统的脑积水治疗方法是
脑脊液(CSF)分流。 CSF分流的终身并发症高且昂贵,每年
医院收费近20亿美元,占所有儿科医院费用的3.1%。作为分流
并发症也会对生活质量产生不利影响,毫不奇怪,对受影响的家庭的调查
脑积水表明,他们迫切需要无分流的治疗选择。最有前途的无分流
婴儿脑积水的治疗是内窥镜的第三室室造口术,脉络丛餐
(ETV+CPC),我们的脑积水临床研究网络(HCRN)和其他证明是安全的
和可行。然而,与分流相比,ETV+CPC的认知结果尚不清楚。我们的数据暗示
大多数家庭都会接受ETV+CPC的风险,有机会摆脱分流的机会,但前提是初始
与分流相比,用ETV+CPC的治疗不会导致认知结果的明显牺牲。和
该U01提案,我们的目标:1。确定在≤12个月校正年龄的婴儿中,脑积水需要
与关闭相比
通过手术后12个月的贝利尺度衡量的婴儿和
幼儿发展(Bayley-III)认知量表,非效率差为1.5。 2a。确定,在
相同的队列,如果ETV+CPC与非内部bayley-III运动/语言尺度相比,分流率相比
Vineland-3量表。 2b。比较其他治疗性能的度量(大脑/心室体积,
治疗失败,住院日,重复手术,使用成像)和治疗臂之间的并发症。
3a。确定ETV+CPC和分流对脑结构连通性的影响,并扩散MR
手术后12个月的call体call体的分数各向异性(FA)。 3b。定义关系
术前大脑/心室体积和脑脊液(CSF)NCAM-1水平与术后水平
手术后12个月,call体FA和Bayley-III认知量表。 3C。定义关系
在大脑/心室体积的变化(术前至术后12个月)之间
术后12个月的call体和皮质脊髓和贝利 - III认知和运动尺度。
为此,我们计划一个RCT,比较脑积水的婴儿中的ETV+CPC和分流,在HCRN内,A
由14个领先的北美小儿神经外科手术中心组成
成功的合作临床研究和RCT在脑积水中。最佳认知结果,主要
因此,对家庭的关注将是我们的主要结果。评估DMRI,经过验证的,无创的
在发育中测量白质微观结构完整性和结构连接的方法
大脑将进一步了解这两种治疗方法的发展后果。这个RCT会
帮助家庭确定对孩子的最佳治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard Holubkov其他文献
Richard Holubkov的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard Holubkov', 18)}}的其他基金
A Placebo-Controlled Effectiveness in INPH Shunting (PENS) Trial
INPH 分流 (PENS) 试验中安慰剂对照的有效性
- 批准号:
10279146 - 财政年份:2021
- 资助金额:
$ 149.22万 - 项目类别:
A Placebo-Controlled Effectiveness in INPH Shunting (PENS) Trial
INPH 分流 (PENS) 试验中安慰剂对照的有效性
- 批准号:
10494229 - 财政年份:2021
- 资助金额:
$ 149.22万 - 项目类别:
Endoscopic versus Shunt Treatment of Hydrocephalus in Infants
婴儿脑积水的内镜与分流治疗
- 批准号:
10706453 - 财政年份:2019
- 资助金额:
$ 149.22万 - 项目类别:
Endoscopic versus Shunt Treatment of Hydrocephalus in Infants
婴儿脑积水的内镜与分流治疗
- 批准号:
10016833 - 财政年份:2019
- 资助金额:
$ 149.22万 - 项目类别:
相似国自然基金
腹腔巨噬细胞通过IL-16信号通路介导子宫内膜异位症慢性腹部疼痛
- 批准号:32371043
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
C/EBPZ调控鸡腹部脂肪组织形成的生物学功能和作用机制研究
- 批准号:32360825
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
面向小器官精准分割的腹部CT影像多器官分割技术研究
- 批准号:62303127
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ABCC2转运蛋白在克氏原螯虾腹部肌肉中抗汞积累特性研究
- 批准号:32302982
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
面向腹部创伤的超声辅助诊断关键技术研究
- 批准号:62371121
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Role of Gastrointestinal GCPII in Visceral Pain Signaling
胃肠道 GCPII 在内脏疼痛信号传导中的作用
- 批准号:
10678103 - 财政年份:2023
- 资助金额:
$ 149.22万 - 项目类别:
Artificial Intelligence powered virtual digital twins to construct and validate AI automated tools for safer MR-guided adaptive RT of abdominal cancers
人工智能支持虚拟数字双胞胎来构建和验证人工智能自动化工具,以实现更安全的 MR 引导的腹部癌症自适应放疗
- 批准号:
10736347 - 财政年份:2023
- 资助金额:
$ 149.22万 - 项目类别:
Fibrosis Beyond the Core: A New Application of MRI to Noninvasively Quantify Whole Kidney Fibrosis
超越核心的纤维化:MRI 无创量化全肾纤维化的新应用
- 批准号:
10796499 - 财政年份:2023
- 资助金额:
$ 149.22万 - 项目类别:
Development of ALM-488 for nerve and ureter visualization during abdominal surgery
开发用于腹部手术期间神经和输尿管可视化的 ALM-488
- 批准号:
10699258 - 财政年份:2023
- 资助金额:
$ 149.22万 - 项目类别: